孕早期贫血及孕晚期贫血缓解与妊娠结局的关联
基于美国商业保险索赔数据库 2018-2023 年 73586 例无遗传性贫血孕妇,在孕 14 周前以血红蛋白/血细胞比容识别孕早期贫血。孕早期贫血与除前置胎盘外的多种不良母儿结局风险升高相关,其中输血风险最高;孕晚期贫血缓解可消除与非输血严重母体并发症的关联,但未消除其他结局关联。
要点
- 孕早期贫血孕妇中 53.4% 持续至孕晚期,46.6% 在孕晚期缓解。
- 持续贫血与非输血严重母体并发症、输血及小于胎龄儿风险升高相关。
- 贫血缓解仍与输血和小于胎龄儿风险升高相关,强调孕前及孕早期纠正贫血。
核心结论
- 孕早期贫血与不良母体及新生儿结局风险升高相关。
- 孕晚期贫血缓解消除了与非输血严重母体并发症的关联,但未消除其他结局的关联。
研究设计与样本
- 使用 Merative Marketscan 商业保险索赔数据库(2018-2023 年)的回顾性队列研究。
- 纳入 73586 例无遗传性贫血的孕妇,以血红蛋白和血细胞比容在孕 14 周前及孕 24 周后识别贫血。
- 采用逆概率加权校正混杂因素后的改良 Poisson 回归估计关联。
主要发现
- 73586 例孕妇中 4.4%(95%CI 4.3-4.6%)存在孕早期贫血。
- 孕早期贫血与除前置胎盘外所有评估的不良结局风险升高相关,输血风险最高(2.4% vs 0.8%;aRR 2.45;95%CI 1.91-3.13)。
- 有孕早期贫血且孕晚期有实验室数值者中,53.4% 为持续贫血,46.6% 为贫血缓解。
- 与无孕早期贫血者相比,持续贫血与非输血严重母体并发症(2.6% vs 1.1%;aRR 1.64;95%CI 1.13-2.37)、输血(2.9% vs 0.8%;aRR 2.60;95%CI 1.84-3.69)及小于胎龄儿(8.5% vs 6.8%;aRR 1.23;95%CI 1.01-1.50)相关。
- 贫血缓解与非输血严重母体并发症无关联(1.6% vs 1.1%;aRR 1.07;95%CI 0.65-1.74),但与输血(1.6% vs 0.8%;aRR 1.64;95%CI 1.01-2.67)及小于胎龄儿(10.0% vs 6.8%;aRR 1.38;95%CI 1.15-1.67)相关。
临床怎么用
- 孕早期应常规筛查血红蛋白和血细胞比容以识别贫血。
- 对孕早期贫血应积极纠正,目标是在孕晚期前实现贫血缓解。
- 即使孕晚期贫血缓解,仍需警惕输血和小于胎龄儿风险。
局限性
- 使用商业保险索赔数据库,结果外推至未参保或公共保险人群受限。
- 贫血识别依赖实验室检测记录,未进行实验室检测者无法分类。
- 无法完全排除未测量混杂因素的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Evidence related to anemia in early pregnancy, and its resolution or persistence by late pregnancy, is limited. We evaluated pregnancy outcomes associated with anemia in early pregnancy and resolution compared with persistence in late pregnancy. METHODS: We used the Merative™ Marketscan ® Commercial Database of nationwide insurance claims (2018-2023) and included pregnant individuals without hereditary anemias. We used hemoglobin and hematocrit to identify anemia in early pregnancy (before 14 weeks of gestation) and late pregnancy (at or after 24 weeks of gestation). Pregnancy outcomes included preeclampsia, placenta previa, placental abruption, severe postpartum hemorrhage, blood products transfusion, cesarean birth, nontransfusion severe maternal morbidity (SMM), spontaneous preterm birth, medically indicated preterm birth, and small-for-gestational-age (SGA) birth weight. We used modified Poisson regression to estimate associations between: 1) anemia in early pregnancy and pregnancy outcomes; and 2) anemia resolution by late pregnancy and pregnancy outcomes, adjusting for confounders by inverse probability weighting. RESULTS: Among 73,586 individuals, 4.4% (95% CI, 4.3-4.6%) had anemia in early pregnancy. Early pregnancy anemia was associated with higher risk of each outcome assessed, with the exception of placenta previa, with the highest associated risk of blood products transfusion (2.4% vs 0.8%; adjusted risk ratio [aRR] 2.45; 95% CI, 1.91-3.13). Of those with early pregnancy anemia and laboratory values in late pregnancy (72.1%), 53.4% had persistent anemia and 46.6% had resolved anemia. Persistent anemia was associated with nontransfusion SMM (2.6% vs 1.1%, aRR 1.64; 95% CI, 1.13-2.37), blood products transfusion (2.9% vs 0.8%, aRR 2.60; 95% CI, 1.84-3.69), and SGA birth weight (8.5% vs 6.8%, aRR 1.23; 95% CI, 1.01-1.50), compared with those without anemia in the first trimester. The resolution of anemia by late pregnancy was not associated with nontransfusion SMM (1.6% vs 1.1%; aRR 1.07; 95% CI, 0.65-1.74) but was associated with blood products transfusion (1.6% vs 0.8%; aRR 1.64; 95% CI, 1.01-2.67) and SGA birth weight (10.0% vs 6.8%; aRR 1.38; 95% CI, 1.15-1.67) compared with those without anemia in the first trimester. CONCLUSION: Anemia in the first trimester was associated with adverse maternal and neonatal outcomes. The resolution of anemia by late pregnancy eliminated the association with nontransfusion SMM but not other outcomes, emphasizing the importance of treating anemia in early pregnancy and before pregnancy.
引用
- Booman, Bateman, Siadat, et al. Pregnancy Outcomes Associated With Anemia in the First Trimester and Anemia Resolution by Late Pregnancy. Obstet Gynecol. 2026. PMID: 41643193. doi:10.1097/AOG.0000000000006183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。